PubMed Health⌕ Search

PubMed · 2773843

Infancy: mental and motor development.

Abstract

In a prospective cohort study of 196 infants from birth to age 15 mo, the relationship of iron status to psychomotor development, the effect of a short-term trial of oral iron or placebo, and the effect of longer-term oral iron therapy was assessed. Development was assessed with the Bayley Scale of Infant Development in anemic, nonanemic, iron-deficient, and control children. Anemic infants had significantly lower indices than did control or nonanemic, iron-deficient infants. Control infants and nonanemic, iron-deficient infants performed comparably. No difference between the effect of oral administration of iron or placebo was noted after 10 d or 3 mo of iron therapy. A hemoglobin concentration of less than 105 g/L and anemia duration greater than 3 mo were correlated with significantly lower motor and mental scores, suggesting that when iron deficiency progresses to anemia, adverse influences in the performance of developmental tests appear and persist, despite iron therapy.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Walter. 1989. Infancy: mental and motor development.. https://doi.org/10.1093/ajcn%2F50.3.655

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

[Erythropoietin is a novel therapeutic option in the treatment of anemia caused by small cell lung cancer].

Anemia is very common among patients with malignant tumors, due to the disease and chemotherapy. Anemia decreases the patient's quality of life. Erythropoietin therapy is accessible in Hungary for the treatment of chemotherapy-induced anemia in patients suffering from small cell lung cancer. In our case report we present the case of a 62-year-old female small cell lung cancer patient with severe anemia, treated by erythropoietin-beta. The erythropoietin treatment provided the possibility of effective chemo- and radiotherapy. The patient's quality of life greatly improved due to the lack of the symptoms of anemia. The adequate use of erythropoietin is of great help to the physician in the management of small cell lung cancer patients, by improving the quality of life.

Anemia, Hypochromic↗

Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice.

Patients with deficiency in ferrochelatase (FECH), the last enzyme of the heme biosynthetic pathway, experience a painful type of skin photosensitivity called erythropoietic protoporphyria (EPP), which is caused by the excessive production of protoporphyrin IX (PPIX) by erythrocytes. Controversial results have been reported regarding hematologic status and iron status of patients with EPP. We thoroughly explored these parameters in Fechm1Pas mutant mice of 3 different genetic backgrounds. FECH deficiency induced microcytic hypochromic anemia without ringed sideroblasts, little or no hemolysis, and no erythroid hyperplasia. Serum iron, ferritin, hepcidin mRNA, and Dcytb levels were normal. The homozygous Fechm1Pas mutant involved no tissue iron deficiency but showed a clear-cut redistribution of iron stores from peripheral tissues to the spleen, with a concomitant 2- to 3-fold increase in transferrin expression at the mRNA and the protein levels. Erythrocyte PPIX levels strongly correlated with serum transferrin levels. At all stages of differentiation in our study, transferrin receptor expression in bone marrow erythroid cells in Fech(m1Pas) was normal in mutant mice but not in patients with iron-deficiency anemia. Based on these observations, we suggest that oral iron therapy is not the therapy of choice for patients with EPP and that the PPIX-liver transferrin pathway plays a role in the orchestration of iron distribution between peripheral iron stores, the spleen, and the bone marrow.

Anemia, Hypochromic↗